Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Vývoj technik magnetické rezonance pro studium poruch nálady a úzkosti

10. listopadu 2026 aktualizováno: National Institute of Mental Health (NIMH)

Vývoj funkčních a strukturních zobrazovacích technik magnetické rezonance pro studium poruch nálady a úzkosti

This study is intended to help develop new MRI imaging techniques for studying mood and anxiety disorders. Researchers believe that depression and anxiety disorders may cause structural and functional changes in the brain. This study will optimize the way MRI scans are collected to look at brain structure and examine how the brain behaves while subjects perform particular tasks. Healthy volunteers and individuals with major depressive disorder may be eligible for this study.

Participants undergo magnetic resonance imaging (MRI) and neuropsychological testing. : Individuals will be asked to participate in an MRI study on one of several scanners. The scanner used will measure blood flow in the brain, concentrations of certain chemicals in the brain, or magnetic properties of the brain. The scan may involve They watching a screen presenting images or doing a task in which they respond to pictures or sounds. Participants may be asked to return for additional scans.

The study also involves neuropsychological tests, which assess cognitive performance. Often, people with mood disorders have subtle changes in performance on these tests that allow researchers to pinpoint where brain abnormalities occur. Before the tests can be used in patients, they must be validated by using healthy subjects. These tests are presented either orally, in written form, or on a computer....

Přehled studie

Detailní popis

Objective

A major component of understanding the pathogenesis of mood and anxiety disorders is expected to involve elucidation of abnormalities in brain structure and function associated with these conditions. Historically post-mortem histopathological and neurochemical assessments constituted the primary methods for investigating abnormalities of brain structure and function in psychiatric disorders. However, the significance of the results from such studies has been limited by the relatively poor availability of specimens from subjects with mood and anxiety disorders who had been unmedicated and clinically well-characterized antemortem. By allowing for in vivo human studies, medical imaging technologies provide efficient, accurate, and non-invasive alternatives for characterizing brain structure and function. The recent rapid development of magnetic resonance imaging (MRI) technology, in particular, has provided powerful tools for assessing a wide range of cerebral physiological and morphological characteristics. To optimally exploit the potential of these rapidly evolving MRI scanning and hardware capabilities in investigations of mood and anxiety disorders, new techniques and applications must be developed and tested. The technical development protocol proposed herein will assess new imaging techniques and hardware, and will develop novel cognitive tasks for application in the study of mood and anxiety disorders. The primary objective of this protocol is the development of MRI experiments for characterizing the physiological correlates of mood and anxiety disorders. In addition, the pilot projects encompassed within this protocol involve the optimization of existing MRI pulse sequences, the application of new pulse sequences for structural and functional MR imaging, and the development of new functional MRI (fMRI) tasks that can elucidate neural function within the cognitive-behavioral domains affected in mood and anxiety disorders. This protocol will also allow testing of existing imaging hardware that can increase the spatial resolution, contrast, and sensitivity of MR images. Such hardware includes the use of multi-channel radio frequency (RF) coils and patient monitoring equipment. Development of these techniques and applications will directly enhance the sensitivity and specificity of MRI studies of mood and anxiety disorders.

Study Population

This study will involve 300 healthy volunteers and 90 patients with major depressive disorder.

Design

This technical development protocol will assess new imaging techniques and hardware, and will develop novel cognitive tasks for application in the study of mood and anxiety disorders. Subjects will have the option to participate in one or several procedures conducted under this protocol, including fMRI, Magnetic Resonance Spectroscopy (MRS), Magnetoencephalography (MEG), behavioral tasks, and rating scales.

Outcome Measures

Primary outcome measures on neuropsychological tests will include parameters such as accuracy and reaction time. Secondary outcome measures will include differences in reaction time or accuracy between different testing conditions. Outcome measures from MRI scanning sessions will include signal-to-noise ratio, contrast-to-noise ratio, structural volumes, metabolite concentrations (in the case of MRS), relaxation times (in the case of relaxometry), and BOLD time series (in the case of fMRI).

Typ studie

Pozorovací

Zápis (Odhadovaný)

390

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

    • Maryland
      • Bethesda, Maryland, Spojené státy, 20892
        • Nábor
        • National Institutes of Health Clinical Center

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let až 65 let (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ano

Pohlaví způsobilá ke studiu

Všechno

Metoda odběru vzorků

Vzorek nepravděpodobnosti

Studijní populace

Adult healthy volunteers and individuals with major depressive disorder will be recruited from the general population.

Popis

  • INCLUSION CRITERIA:

Healthy Controls

  • Male and female subjects between 18 and 65 years of age
  • Subjects must be able to give written informed consent prior to participation in this study.
  • Subjects who do not currently meet and have never met criteria for any major psychiatric disorder, and who have no known first degree relatives with mood disorders.
  • For cognitive experiments utilizing language stimuli only native English speakers will be enrolled.

Major Depressive Disorder

  • Male and female subjects between 18 and 65 years of age.
  • Subjects have been found eligible for other ETPB research protocols according to 01-M-0254.
  • Subjects must fulfill DSM-IV or V criteria for Major Depression based on clinical assessment and confirmed by a structured diagnostic interview (SCID-P).
  • Subjects must be able to give written informed consent prior to participation in this study.
  • For cognitive experiments utilizing language stimuli, only native English speakers will be enrolled.

EXCLUSION CRITERIA:

Healthy Control

  • Subjects with major medical or neurological disorders expected to influence cerebral blood flow or morphology, or taking any medication that is likely to influence the imaging parameters-of-interest within 3 weeks of scanning.
  • Women who are pregnant are excluded from the study. Subjects will undergo pregnancy testing no more than 24 hours prior to MRI scanning.
  • Subjects with contraindication to MRI scanning such as aneurysm clips, implanted neural stimulator, implanted cardiac pacemaker or auto-defibrillator, cochlear implant, or ocular foreign body.
  • A history of drug or alcohol abuse within 1 year or a lifetime history of drug or alcohol dependence (DSM-IV) or alcohol use disorder (DSM-V equivalent).

Major Depressive Disorder

  • Presence of Axis 1 psychiatric diagnosis other than Major Depression or an Axis 2 disorder
  • Subjects with major medical or neurological disorders expected to influence cognitive function or are taking any drugs likely to affect mood or cognitive function within 1 week of study participation. Depressed subjects will not be tapered/withdrawn from medications under this study.
  • A history of drug or alcohol abuse within 1 year or a lifetime history of drug or alcohol dependence (DSM-IV) or alcohol use disorder (DSM-V equivalent).
  • Subjects with major medical or neurological disorders expected to influence cerebral blood flow or morphology.
  • Women who are pregnant or breastfeeding will be excluded from MRI portions of the study. Subjects will undergo pregnancy testing no more than 24 hours prior to MRI scanning.
  • Subjects with contraindication to MRI scanning such as aneurysm clips, implanted neural stimulator, implanted cardiac pacemaker or auto-defibrillator, cochlear implant, or ocular foreign body.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Observační modely: COHORT
  • Časové perspektivy: OTHER

Kohorty a intervence

Skupina / kohorta
Intervence / Léčba
Healthy Volunteer

Healthy Volunteer/control group

Non-significant risk device used for brain imaging

Major Depressive Disorder

Individuals with Major Depressive Disorder

Non-significant risk device used for brain imaging

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
BOLD time series
Časové okno: Varies based on experiment

Magnetic Resonance Imaging data

Varies based on experiment
Structural volumes
Časové okno: Varies based on experiment

Magnetic Resonance Imaging data

Varies based on experiment
Accuracy
Časové okno: Varies based on experiment

Neuropsychological testing data

Varies based on experiment
Contrast-to-noise ratio
Časové okno: Varies based on experiment

Magnetic Resonance Imaging data

Varies based on experiment
Signal-to-noise ratio
Časové okno: Varies based on experiment

Magnetic Resonance Imaging data

Varies based on experiment
Relaxation times
Časové okno: Varies based on experiment

Reflexometry data

Varies based on experiment
Metabolite concentrations
Časové okno: Varies based on experiment

Magnetoencephalography data

Varies based on experiment
Reaction time
Časové okno: Varies based on experiment

Neuropsychological testing data

Varies based on experiment

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Reaction time between testing conditions
Časové okno: Varies based on experiment

Neuropsychological testing data

Varies based on experiment
Accuracy between testing conditions
Časové okno: Varies based on experiment

Neuropsychological testing data

Varies based on experiment

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Vyšetřovatelé

  • Vrchní vyšetřovatel: Allison C Nugent, Ph.D., National Institute of Mental Health (NIMH)

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

6. prosince 2006

Termíny zápisu do studia

První předloženo

7. listopadu 2006

První předloženo, které splnilo kritéria kontroly kvality

7. listopadu 2006

První zveřejněno (Odhadovaný)

8. listopadu 2006

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

12. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

10. listopadu 2026

Naposledy ověřeno

1. října 2026

Více informací

Termíny související s touto studií

Další relevantní podmínky MeSH

Další identifikační čísla studie

  • 070021
  • 07-M-0021

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

Clinical, demographic, and phenotype participant data collected during the trial, after deidentification.

Časový rámec sdílení IPD

Sharing my start at any time during data collection, no later 1 year following completion of the study.

Kritéria přístupu pro sdílení IPD

Fully de-identified data may be shared on publicly available data repositories. The PI will review additional requests for data not shared in repositories.

Typ podpůrných informací pro sdílení IPD

  • MÍZA
  • ANALYTIC_CODE

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit